Ct-p13 sc (infliximab) (DrugBank: Infliximab)
25 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
35 | 天疱瘡 | 0 |
37 | 膿疱性乾癬(汎発型) | 0 |
38 | スティーヴンス・ジョンソン症候群 | 0 |
39 | 中毒性表皮壊死症 | 0 |
40 | 高安動脈炎 | 0 |
41 | 巨細胞性動脈炎 | 0 |
42 | 結節性多発動脈炎 | 0 |
43 | 顕微鏡的多発血管炎 | 0 |
45 | 好酸球性多発血管炎性肉芽腫症 | 0 |
46 | 悪性関節リウマチ | 0 |
49 | 全身性エリテマトーデス | 0 |
50 | 皮膚筋炎/多発性筋炎 | 0 |
55 | 再発性多発軟骨炎 | 0 |
56 | ベーチェット病 | 0 |
65 | 原発性免疫不全症候群 | 0 |
84 | サルコイドーシス | 0 |
85 | 特発性間質性肺炎 | 0 |
95 | 自己免疫性肝炎 | 0 |
96 | クローン病 | 2 |
97 | 潰瘍性大腸炎 | 1 |
98 | 好酸球性消化管疾患 | 0 |
162 | 類天疱瘡(後天性表皮水疱症を含む。) | 0 |
164 | 眼皮膚白皮症 | 0 |
269 | 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群 | 0 |
271 | 強直性脊椎炎 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-jRCT2031200117 | 01/09/2020 | 11/09/2020 | A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderately to Severely Active Crohns Disease | A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderately to Severely Active Crohns Disease | Crohns Disease | Biological: CT-P13 SC (Infliximab) Other: Placebo SC | Ishida Tetsuya | Celltrion | Recruiting | >= 18age old | <= 75age old | Both | 600 | Phase 3 | Austria;Bulgaria;Croatia;Japan;US;Latvia;Czech Republic;France;Poland;Germany;Greece;Hungary;Spain |
2 | NCT03945019 (ClinicalTrials.gov) | October 28, 2019 | 8/5/2019 | CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease | A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease | Crohn's Disease | Biological: CT-P13 SC (Infliximab);Other: Placebo SC | Celltrion | NULL | Recruiting | 18 Years | 75 Years | All | 600 | Phase 3 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04205643 (ClinicalTrials.gov) | September 2, 2020 | 18/12/2019 | CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis | A Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | Biological: CT-P13 SC (Infliximab);Other: Placebo SC | Celltrion | NULL | Recruiting | 18 Years | 75 Years | All | 615 | Phase 3 | Poland |